SG11201905622VA - Subcutaneous her2 antibody formulations - Google Patents

Subcutaneous her2 antibody formulations

Info

Publication number
SG11201905622VA
SG11201905622VA SG11201905622VA SG11201905622VA SG11201905622VA SG 11201905622V A SG11201905622V A SG 11201905622VA SG 11201905622V A SG11201905622V A SG 11201905622VA SG 11201905622V A SG11201905622V A SG 11201905622VA SG 11201905622V A SG11201905622V A SG 11201905622VA
Authority
SG
Singapore
Prior art keywords
perjeta
cohort
dose
genentech
international
Prior art date
Application number
SG11201905622VA
Other languages
English (en)
Inventor
Jennifer Eng-Wong
Whitney Kirschbrown
Tarik Khan
Jasper Lin
Sreedhara Alavattam
Amit Garg
Sarah Heeson
Tanja Badovinac-Crnjevic
Christine Wurth
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61800658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201905622V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of SG11201905622VA publication Critical patent/SG11201905622VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11201905622VA 2017-01-17 2018-01-16 Subcutaneous her2 antibody formulations SG11201905622VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762447359P 2017-01-17 2017-01-17
PCT/US2018/013854 WO2018136412A2 (en) 2017-01-17 2018-01-16 Subcutaneous her2 antibody formulations

Publications (1)

Publication Number Publication Date
SG11201905622VA true SG11201905622VA (en) 2019-08-27

Family

ID=61800658

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202011384XA SG10202011384XA (en) 2017-01-17 2018-01-16 Subcutaneous her2 antibody formulations
SG11201905622VA SG11201905622VA (en) 2017-01-17 2018-01-16 Subcutaneous her2 antibody formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202011384XA SG10202011384XA (en) 2017-01-17 2018-01-16 Subcutaneous her2 antibody formulations

Country Status (26)

Country Link
US (4) US10849849B2 (ja)
EP (2) EP3570884B1 (ja)
JP (4) JP6741875B2 (ja)
KR (5) KR20190104554A (ja)
CN (4) CN115089704A (ja)
AU (3) AU2018210312B2 (ja)
CA (1) CA3047349C (ja)
CR (1) CR20190376A (ja)
CY (1) CY1123586T1 (ja)
DK (1) DK3570884T3 (ja)
ES (1) ES2835376T3 (ja)
HR (1) HRP20201866T1 (ja)
HU (1) HUE052551T2 (ja)
IL (2) IL288948B1 (ja)
LT (1) LT3570884T (ja)
MA (2) MA47313B1 (ja)
MX (2) MX2019008350A (ja)
MY (1) MY189536A (ja)
PT (1) PT3570884T (ja)
RS (1) RS61236B1 (ja)
RU (1) RU2750821C2 (ja)
SG (2) SG10202011384XA (ja)
SI (1) SI3570884T1 (ja)
TW (2) TWI841849B (ja)
UA (1) UA123292C2 (ja)
WO (1) WO2018136412A2 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
ES2835376T3 (es) 2017-01-17 2021-06-22 Genentech Inc Formulaciones de anticuerpos frente a HER2 subcutáneas
CN117180422A (zh) 2017-03-02 2023-12-08 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
EP3824904A4 (en) * 2018-07-19 2021-08-25 Celltrion, Inc. STABLE LIQUID PHARMACEUTICAL PREPARATION
BR112021004590A2 (pt) 2018-09-12 2021-05-25 Silverback Therapeutics, Inc. composições para o tratamento de doença com conjugados imunoestimuladores
WO2020060179A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 완충화제를 포함하지 않는 트라스투주맙 항체 안정화 제제
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
US20220249685A1 (en) 2019-06-19 2022-08-11 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
KR20210059646A (ko) * 2019-11-15 2021-05-25 삼성바이오에피스 주식회사 항체 의약품용 액상 조성물
CR20220322A (es) * 2019-12-09 2022-07-28 Genentech Inc Formulaciones de anticuerpos anti-pd-l1
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN113827717A (zh) * 2020-06-23 2021-12-24 三生国健药业（上海）股份有限公司 抗her2单克隆抗体冻干制剂及制备方法
MX2022015884A (es) * 2020-06-29 2023-04-03 Genentech Inc Combinacion de dosis fija de pertuzumab mas trastuzumab.
EP4175673A1 (en) 2020-07-01 2023-05-10 ARS Pharmaceuticals Inc. Anti-asgr1 antibody conjugates and uses thereof
CN114652687B (zh) * 2020-12-23 2024-02-20 盛禾(中国)生物制药有限公司 一种去岩藻糖基化的抗Her2抗体冻干粉针剂的制备方法
WO2022146947A1 (en) * 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023019556A1 (zh) * 2021-08-20 2023-02-23 齐鲁制药有限公司 一种高浓度抗her2的抗体制剂及其用途
WO2023178019A1 (en) 2022-03-14 2023-09-21 Genentech, Inc. Combination therapies for breast cancer
KR20230150203A (ko) * 2022-04-20 2023-10-30 주식회사 알토스바이오로직스 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4933294A (en) 1984-01-30 1990-06-12 Icrf Patents Limited Method of detecting truncated epidermal growth factor receptors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
ATE155813T1 (de) 1989-05-19 1997-08-15 Genentech Inc Her2 extrazellulare domäne
DE68926248T2 (de) 1989-09-29 1996-12-19 Oncogene Science Inc p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ES2337091T3 (es) 1996-11-27 2010-04-20 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteina.
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CA2324494A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
KR100960211B1 (ko) 1998-05-06 2010-05-27 제넨테크, 인크. 이온 교환 크로마토그래피에 의한 단백질 정제 방법
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
CA2374085C (en) 1999-05-14 2015-12-29 Genentech, Inc. Tumour treatment with anti-erbb2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU779209B2 (en) 1999-06-25 2005-01-13 Genentech Inc. Treating prostate cancer with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
IL148114A0 (en) 1999-08-27 2002-09-12 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US20200048362A1 (en) 2000-03-16 2020-02-13 Immunogen, Inc. Methods of treatment using anti-erbb antibody-maytansinoid conjugates
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
CN102698265A (zh) 2000-05-19 2012-10-03 杰南技术公司 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
EP1345968A2 (en) 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US6695940B2 (en) 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
EP1300146A1 (en) 2001-10-03 2003-04-09 Boehringer Ingelheim International GmbH Pharmaceutical composition for the treatment of animal mammary tumors
US20040048525A1 (en) 2002-01-28 2004-03-11 Sagucio Esteban N. Watercycle for wet rider
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
CN101711866A (zh) 2002-07-15 2010-05-26 健泰科生物技术公司 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法
US6982719B2 (en) 2002-07-15 2006-01-03 Sun Microsystems, Inc. Switching sample buffer context in response to sample requests for real-time sample filtering and video generation
US7129840B2 (en) 2002-09-03 2006-10-31 Ricoh Company, Ltd. Document security system
ES2527616T3 (es) 2002-09-11 2015-01-27 Genentech, Inc. Purificación de anticuerpos anti-HER2
AU2003295798B2 (en) 2002-11-21 2009-09-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
TW555245U (en) 2003-01-29 2003-09-21 Hon Hai Prec Ind Co Ltd Cable connector assembly
PL2163643T3 (pl) 2003-03-05 2015-06-30 Halozyme Inc Rozpuszczalna glikoproteina o aktywności hialuronidazy (sHASEGP), sposób jej wytwarzania, zastosowania oraz zawierające ją kompozycje farmaceutyczne
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050025753A1 (en) 2003-04-30 2005-02-03 Wei Han Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
EP1648940B1 (en) 2003-07-28 2016-04-27 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
ATE540696T1 (de) 2004-04-08 2012-01-15 David B Agus Erbb2-antagonisten für die tumorschmerztherapie
US7195440B2 (en) 2004-05-27 2007-03-27 Lambert Charles F Agricultural silo auger system apparatus and method
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
PT1771482E (pt) 2004-07-22 2014-11-03 Genentech Inc Composição de anticorpo her2
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
AU2006216732C1 (en) 2005-02-23 2017-07-20 Genentech, Inc. Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
TW200642695A (en) 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US20090148401A1 (en) 2005-12-05 2009-06-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CA2654584A1 (en) 2006-06-05 2007-12-21 Genentech, Inc. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
WO2008022746A1 (en) 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-vegf antibody
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
EP1997534A1 (en) 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
MX2009012838A (es) 2007-06-06 2009-12-11 Hoffmann La Roche Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
RU2523890C2 (ru) 2007-09-12 2014-07-27 Дженентек, Инк. Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения
PT2215117E (pt) 2007-10-30 2015-04-01 Genentech Inc Purificação de anticorpo por cromatografia de troca de catiões
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US20090226455A1 (en) 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and her antagonists
KR20210131473A (ko) 2008-03-18 2021-11-02 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
US9235334B2 (en) 2008-05-09 2016-01-12 Genesis Industries, Llc Managing landbases and machine operations performed thereon
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
SG10201507044PA (en) 2009-05-29 2015-10-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20140044709A1 (en) 2010-12-09 2014-02-13 Genentech, Inc. Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
JP2012228007A (ja) * 2011-04-15 2012-11-15 Asmo Co Ltd バスバー装置、ステータ、モータ及びステータの製造方法
CN116236569A (zh) 2011-10-14 2023-06-09 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
KR101909801B1 (ko) 2012-06-08 2018-10-18 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
CN102961745B (zh) * 2012-09-27 2015-02-18 苏州康聚生物科技有限公司 抗体组合物制剂及其应用
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
NZ720515A (en) 2013-12-17 2022-12-23 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
SG10201809411PA (en) 2014-04-25 2018-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
WO2016011422A2 (en) * 2014-07-17 2016-01-21 Czerniecki Brian J Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3
AU2015318001B2 (en) 2014-09-15 2021-03-25 Genentech, Inc. Antibody formulations
MX2017003472A (es) 2014-09-17 2017-10-31 Genentech Inc Inmunoconjugados que comprenden anticuerpos anti-her2.
CN104784105A (zh) * 2015-04-17 2015-07-22 北京大学 一种单克隆抗体药物的凝胶组合物
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
EP3267657A1 (de) 2016-07-06 2018-01-10 Siemens Aktiengesellschaft Netzwerksystem, cloud-anschluss und verfahren zur identifikation von netzwerkgeräten
AU2017355432A1 (en) 2016-11-04 2019-05-16 F. Hoffmann-La Roche Ag Treatment of HER2-positive breast cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
ES2835376T3 (es) 2017-01-17 2021-06-22 Genentech Inc Formulaciones de anticuerpos frente a HER2 subcutáneas
CN117180422A (zh) 2017-03-02 2023-12-08 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
TW201902509A (zh) 2017-04-24 2019-01-16 美商建南德克公司 Erbb2/her2突變
MX2022015884A (es) 2020-06-29 2023-04-03 Genentech Inc Combinacion de dosis fija de pertuzumab mas trastuzumab.
EP4182688A1 (en) 2020-07-14 2023-05-24 F. Hoffmann-La Roche AG Assays for fixed dose combinations
KR20230118587A (ko) 2020-12-11 2023-08-11 제넨테크, 인크. Her2 암 치료를 위한 병용 요법

Also Published As

Publication number Publication date
IL288948A (en) 2022-02-01
CA3047349A1 (en) 2018-07-26
RU2019125238A (ru) 2021-02-19
US20240269064A1 (en) 2024-08-15
KR20210134432A (ko) 2021-11-09
JP2020515519A (ja) 2020-05-28
ES2835376T3 (es) 2021-06-22
SI3570884T1 (sl) 2021-02-26
US11654105B2 (en) 2023-05-23
KR20190104554A (ko) 2019-09-10
CN111714630B (zh) 2021-11-09
AU2020203066A1 (en) 2020-05-28
KR20200113292A (ko) 2020-10-06
AU2023210566A1 (en) 2023-08-24
TWI729259B (zh) 2021-06-01
JP2023145459A (ja) 2023-10-11
JP2021006526A (ja) 2021-01-21
RU2019125238A3 (ja) 2021-02-19
LT3570884T (lt) 2020-12-10
UA123292C2 (uk) 2021-03-10
EP3868404A1 (en) 2021-08-25
PT3570884T (pt) 2020-11-24
RS61236B1 (sr) 2021-01-29
NZ754848A (en) 2020-10-30
CN111714630A (zh) 2020-09-29
CA3047349C (en) 2020-09-22
WO2018136412A2 (en) 2018-07-26
IL267896B (en) 2022-01-01
IL288948B1 (en) 2024-08-01
TWI841849B (zh) 2024-05-11
SG10202011384XA (en) 2021-01-28
IL267896A (en) 2019-09-26
CN117752782A (zh) 2024-03-26
KR20240010538A (ko) 2024-01-23
JP6769687B1 (ja) 2020-10-14
MX2019008350A (es) 2019-11-11
US20230092354A1 (en) 2023-03-23
EP3570884A2 (en) 2019-11-27
TW202138007A (zh) 2021-10-16
DK3570884T3 (da) 2020-11-30
CN110167594A (zh) 2019-08-23
JP6741875B2 (ja) 2020-08-19
CN110167594B (zh) 2023-11-21
MA47313B1 (fr) 2020-12-31
US20210085597A1 (en) 2021-03-25
HUE052551T2 (hu) 2021-05-28
WO2018136412A3 (en) 2018-11-15
MX2020008977A (es) 2020-09-28
AU2018210312B2 (en) 2020-03-19
US10849849B2 (en) 2020-12-01
US20180296470A1 (en) 2018-10-18
TW201834686A (zh) 2018-10-01
CR20190376A (es) 2019-11-20
RU2750821C2 (ru) 2021-07-05
MA56006A (fr) 2022-05-04
CN115089704A (zh) 2022-09-23
MY189536A (en) 2022-02-16
JP2020186239A (ja) 2020-11-19
HRP20201866T1 (hr) 2021-01-22
KR20220162863A (ko) 2022-12-08
MA47313A (fr) 2019-11-27
AU2018210312A1 (en) 2019-07-04
EP3570884B1 (en) 2020-09-30
CY1123586T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
SG11201905622VA (en) Subcutaneous her2 antibody formulations
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201903946SA (en) Devices and methods for slurry generation
SG11201901961SA (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201806340YA (en) Zika virus vaccine
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201811432WA (en) Rna for cancer therapy
SG11201805954WA (en) Methods for modulating intestinal microbiota
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201407512VA (en) High-concentration monoclonal antibody formulations
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201811559WA (en) Cancer treatment combinations
SG11201909676WA (en) Treatment of her2 positive cancers
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201804268RA (en) Conjugates of quaternized tubulysin compounds
SG11201810793XA (en) Pharmaceutical combinations
SG11201906543RA (en) HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY